R&D | October 28, 2025
MilliporeSigma partners with Promega to advance 3-D cell drug discovery technologies
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world
Several technologies for hemoglobinopathies are being transferred to commercial partners
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Subscribe To Our Newsletter & Stay Updated
